



To be completed by the Office of the Secretary of the House of Delegates

Item No.: 3
Date received: 11/19/2015
Time received: 9:56 AM

**American Pharmacists Association
House of Delegates – Baltimore, MD
March 4 - 7, 2016**

NEW BUSINESS

(To be submitted and introduced by Delegates only)

Introduced by: Adriane Irwin, on behalf of the 2016 APhA House of Delegates Policy Review Committee
(Name)

11/19/15
(Date)

APhA Policy Review Committee
(Organization)

Subject: Combating Drug Abuse

Motion: We, the members of the Policy Review Committee, urge the 2016 House of Delegates to adopt the following policy statement language that updates and combines two existing policies into a single comprehensive statement. If the proposed policy is approved, then the current individual 2005 and 2006 policy statements will become archived.

1. APhA supports legislative, regulatory, and private sector efforts that include input from pharmacists to balance the need for patient/consumer access to medications for legitimate medical purposes with the need to prevent diversion and abuse.
2. APhA supports consumer sales limits of nonprescription drug products that may be illegally converted into drugs for illicit use such as methamphetamine precursors.
3. APhA encourages education of all personnel involved in the distribution chain of nonprescription products concerning the potential for certain products, such as methamphetamine precursors, to be illegally converted into drugs for illicit use. APhA supports patient/consumer education of consequences of methamphetamine abuse.
4. APhA supports public and private initiatives that result in increased funding to address the escalating needs for drug abuse treatment and prevention.
5. APhA supports stringent enforcement of criminal laws against individuals who engage in the trafficking of illicit drugs including methamphetamine and methamphetamine precursors.

Background:

The 2015 – 2016 Policy Review Committee reviewed the policy statements: “2006 Conversion of Nonprescription Products Into Drugs of Abuse” and “2005 Efforts to Limit Methamphetamine Access.” The committee felt there was significant overlap between the two policies and this was an opportunity to combine policy into a single comprehensive policy. Outlined below is a comparison between the existing APhA policies and with the combined policy.

2006 Conversion of Nonprescription Products Into Drugs of Abuse	2005 Efforts to Limit Methamphetamine Access	Combined Policy (Motion Above)
<p>1. APhA supports legislative, <u>regulatory, and private sector efforts that include input from pharmacists</u> to balance the need for patient/consumer access to medications for legitimate medical purposes with the need to prevent diversion and abuse.</p>	<p>1. APhA supports legislation that balances the need for patient/consumer access to medications for legitimate medical purposes with the need to prevent diversion and abuse.</p>	<p>1. APhA supports legislative, regulatory, and private sector efforts that include input from pharmacists to balance the need for patient/consumer access to medications for legitimate medical purposes with the need to prevent diversion and abuse.</p> <p>Notes: This is full statement 1 from the 2006 policy.</p>
<p>2. APhA supports <u>consumer sales limits of nonprescription drug products that may be illegally converted into drugs for illicit use.</u></p>	<p>3. APhA supports <u>retail sales limits of non-prescription products that contain methamphetamine precursors to prevent diversion.</u></p>	<p>2. APhA supports consumer sales limits of nonprescription drug products that may be illegally converted into drugs for illicit use <u>such as methamphetamine precursors.</u></p> <p>Notes: Differing verbiage was kept from 2006 policy with underlined text then added.</p>
<p>3. APhA <u>encourages</u> education of <u>all personnel</u> involved in the distribution chain of <u>nonprescription products concerning the potential for certain products to be illegally converted into drugs for illicit use.</u></p>	<p>4. APhA <u>supports</u> education of <u>employees</u> involved in the distribution chain of <u>methamphetamine precursors about diversion, methamphetamine abuse and prevention of abuse.</u> APhA supports patient/consumer education of consequences of methamphetamine abuse.</p>	<p>3. APhA encourages education of all personnel involved in the distribution chain of nonprescription products concerning the potential for certain products, <u>such as methamphetamine precursors,</u> to be illegally converted into drugs for illicit use. APhA supports patient/consumer education of consequences of methamphetamine abuse.</p> <p>Notes: 1st Statement: Differing verbiage was kept from 2006 policy with underlined text then added. 2nd Statement: Kept from 2005 policy.</p>

<p>4. APhA supports public and private initiatives that result in increased funding to address the escalating needs for drug abuse treatment and prevention.</p>	<p>5. APhA supports public and private initiatives that result in increased funding to address the escalating needs for drug abuse treatment and prevention.</p>	<p>4. APhA supports public and private initiatives that result in increased funding to address the escalating needs for drug abuse treatment and prevention.</p> <p>Notes: There are no differences between the two policies.</p>
	<p>2. APhA supports stringent enforcement of criminal laws against individuals who engage in the illegal trafficking of methamphetamine and methamphetamine precursors.</p>	<p>5. APhA supports stringent enforcement of criminal laws against individuals who engage in the illegal trafficking of <u>illicit drugs including methamphetamine and methamphetamine precursors.</u></p> <p>Notes: Policy slightly edited to make consistent with broader nature of policy.</p>

Current APhA Policy & Bylaws:

2006 Conversion of Nonprescription Products Into Drugs of Abuse

1. APhA supports legislative, regulatory, and private sector efforts that include input from pharmacists to balance the need for patient/consumer access to medications for legitimate medical purposes with the need to prevent diversion and abuse.
2. APhA supports consumer sales limits of nonprescription drug products that may be illegally converted into drugs for illicit use.
3. APhA encourages education of all personnel involved in the distribution chain of nonprescription products concerning the potential for certain products to be illegally converted into drugs for illicit use.
4. APhA supports public and private initiatives that result in increased funding to address the escalating needs for drug abuse treatment and prevention.

(JAPhA N46(5):561 September/October 2006)(Reviewed 2011)

2005 Efforts to Limit Methamphetamine Access

1. APhA supports legislation that balances the need for patient/consumer access to medications for legitimate medical purposes with the need to prevent diversion and abuse.
2. APhA supports stringent enforcement of criminal laws against individuals who engage in the illegal trafficking of methamphetamine and methamphetamine precursors.
3. APhA supports retail sales limits of non-prescription products that contain methamphetamine precursors to prevent diversion.
4. APhA supports education of employees involved in the distribution chain of methamphetamine precursors about diversion, methamphetamine abuse and prevention of abuse. APhA supports patient/consumer education of consequences of methamphetamine abuse.
5. APhA supports public and private initiatives that result in increased funding to address the escalating needs for drug abuse treatment and prevention.

(JAPhA NS45(5):555 September/October 2005)(Reviewed 2006)(Reviewed 2011)

New Business Items are due to the Speaker of the House by **February 3, 2016** (30 days prior to the start of the first House session). Consideration of urgent items can be presented with a suspension of the House Rules at the session where New Business will be acted upon. Please submit New Business Items to the Speaker of the House via email at hod@aphanet.org.